Protective effect of Livergol® on reproductive complications in a rat model of experimental cholestasis

Document Type : Original Article

Authors

1 Department of Surgery and Diagnostic Imaging, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

2 Department of Basic Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

10.30466/vrf.2026.2078938.5005
Abstract
Cholestasis, a multi-faceted liver complication arising from an imbalance in bile production and secretion, can lead to damage in extra-hepatic organs, including the reproductive system. This study aimed to investigate the therapeutic potential of Livergol®, a silymarin-based drug, in the reproductive complications induced by experimental cholestasis in mature male rats. Twenty adults male Wistar rats were randomly divided into four groups (n = 5), including group 1 (control) remained untreated, group 2 (sham) underwent laparotomy and bile duct manipulation without ligation, group 3 (cholestasis) underwent bile duct ligation (BDL) to induce experimental cholestasis, and group 4 (cholestasis + Livergol®) received oral Livergol® (300 mg kg-1) for 4 weeks post-BDL. After the study period, testicular histopathology was evaluated using Johnsen's score and the Cosentino criterion. Epididymal sperm parameters, including count, viability, and motility, were also assessed. The BDL-induced cholestasis caused significant testicular damage, evidenced by a decreased Johnsen's score and an increased Cosentino criterion. It also led to a significant reduction in sperm count, viability, and motility. Treatment with Livergol® significantly ameliorated these effects, leading to a higher Johnsen's score, a lower Cosentino criterion, and marked improvements in all evaluated sperm parameters compared to the untreated cholestatic group. Oral administration of Livergol® effectively attenuates testicular damage and improves spermatogenesis and sperm quality in rats with experimental cholestasis. These findings suggest Livergol® as a promising protective agent against cholestasis-induced reproductive toxicity, likely due to the anti-oxidant properties of its active component, silymarin.

Keywords

Subjects

1.     Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139(5): 1481-1496.
2.     Foresta C, Schipilliti M, Ciarleglio FA, et al. Male hypo-gonadism in cirrhosis and after liver transplantation. J Endocrinol Invest 2008; 31(5): 470-478.
3.     Saad RA, Mahmoud YI. Ursodeoxycholic acid alleviates cholestasis-induced histophysiological alterations in the male reproductive system of bile duct-ligated rats. Reprod Toxicol 2014; 50: 87-97.
4.     Baptissart M, Vega A, Martinot E, et al. Bile acids alter male fertility through G-protein–coupled bile acid receptor 1 signaling pathways in mice. Hepatology 2014; 60(3): 1054-1065.
5.     Ommati MM, Farshad O, Niknahad H, et al. Cholestasis-associated reproductive toxicity in male and female rats: the fundamental role of mitochondrial impairment and oxidative stress. Toxicol Lett 2019; 316: 60-72.
6.     Yoshioka K, Sasaki M, Imai S, et al. Testicular atrophy after bile duct ligation in chickens. Vet Pathol 2004; 41(1): 68-72.
7.     Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.) - chemistry, bioavailability, and metabolism. Molecules 2017; 22(11): 1942. doi: 10.3390/molecules22111942.
8.     Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012; 308(3): 274-282.
9.     Talbi A, Khelili K, Feriel R, et al. The benefit of Silybum marianum in ethanol-induced reprotoxicity of male Wistar rat. Braz J Pharm Sci 2022; 58: e19264. doi: 10.1590/s2175-97902022e19264.
10. Abedi H, Kargar Jahromi H, Hashemi SMA, et al. Effect of silymarin on spermatogenesis process in rats. IJMRHS 2016; 5: 146-150.
11. Niakan M, Johari H, Shariati M. Effect of livergol on liver function and histopathological changes in doxorubicin-treated rats. IRCMJ2023; 25(1): e189066. doi: 10.32592/ircmj.2023.25.1.2178.
12. Rioux KP, Le T, Swain MG. Decreased orexigenic response to neuropeptide Y in rats with obstructive cholestasis. Am J Physiol Gastrointest Liver Physiol 2001; 280(3): G449-G456.
13. Zambrano E, Rodríguez-González GL, Guzmán C,et al. Maternal low protein diet during pregnancy and lactation impairs male reproductive development. J Physiol 2005; 563(Pt 1): 275-284.
14. Ghabeli-Zaherkandi S, Najafi G, Shalizar-Jalali A, et al. Effect of glabridin on sperm traits, testicular oxidative status, and in vitro fertilization in diabetic mature mice: a controlled experimental study. Vet Res Forum 2026; 17(1): 57-62.
15. Noori-Abd N, Najafi-Tazekand G, Shalizar-Jalali A, et al. Protective effects of ellagic acid on oxidative stress and in vitro fertilization in a murine model of varicocele. Iran J Vet Surg 2025; 20(2): 137-143.
16. Farjah MH, Behfar M, Soleimanzadeh-Azad A, et al. Evaluation of chemical castration by intra-testicular injection of zinc-doped carbon dots in mature rats. Vet Res Forum 2025; 16(12): 681-689.
17. Cosentino MJ, Nishida M, Rabinowitz R, et al. Histopathology of prepubertal rat testes subjected to various durations of spermatic cord torsion. J Androl 1986; 7(1): 23-31.
18. Moshtaghion SM, Malekinejad H, Razi M, et al. Silymarin protects from varicocele-induced damages in testis and improves sperm quality: evidence for E2f1 involvement. Syst Biol Reprod Med 2013; 59(5): 270-280.
19. Nasimi Z, Momeni HR, Etemadi T, et al. In vitro coexposure of silymarin with lithium chloride preserves human sperm quality: a useful approach to reduce oxidative damages. Andrologia 2023; 2023: 8838280. doi: 10.1155/2023/8838280.
20. Singh M, Kadhim MM, Turki Jalil A, et al. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity. Cancer Cell Int 2023; 23(1): 88. doi: 10.1186/s12935-023-02936-4.
Volume 17, Issue 8
August 2026
Pages 559-564

  • Receive Date 25 November 2025
  • Revise Date 17 February 2026
  • Accept Date 24 May 2026